TrivarX (CHIA:TRI) - Stock Price, News & Analysis

TRI Stock Overview

A health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. More details

TRI fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap (A$7M)

Makes less than USD$1m in revenue (A$889K)

Has less than 1 year of cash runway

Earnings have declined by 2.4% per year over past 5 years

+ 2 more risks

TrivarX Limited Competitors

Intelicare Holdings

ASX:ICR

AU$5.4m

Global Health

ASX:GLH

AU$8.0m

TALi Digital

ASX:TD1

AU$4.9m

Visionflex Group

ASX:VFX

AU$11.7m

Price History & Performance

Summary of all time highs, changes and price drops for TrivarX
Historical stock prices
Current Share Price	AU$0.016
52 Week High	AU$0.045
52 Week Low	AU$0.014
Beta	0.92
11 Month Change	-5.88%
3 Month Change	-23.81%
1 Year Change	n/a
33 Year Change	-88.57%
5 Year Change	-93.33%
Change since IPO	-99.73%

Recent updates

Shareholder Returns

	TRI	AU Healthcare Services	AU Market
7D	-5.9%	5.3%	0.9%
1Y	n/a	129.1%	18.4%

Return vs Industry: Insufficient data to determine how TRI performed against the Australian Healthcare Services industry.

Return vs Market: Insufficient data to determine how TRI performed against the Australian Market.

Price Volatility

Is TRI's price volatile compared to industry and market?
TRI volatility
TRI Average Weekly Movement	14.8%
Healthcare Services Industry Average Movement	9.1%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.3%

Stable Share Price: TRI's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: Insufficient data to determine TRI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	n/a	n/a	trivarx.com

TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023.

TrivarX Limited Fundamentals Summary

How do TrivarX's earnings and revenue compare to its market cap?
TRI fundamental statistics
Market cap	AU$7.31m
Earnings (TTM)	-AU$1.43m
Revenue (TTM)	AU$888.83k

8.2x

P/S Ratio

-5.1x

P/E Ratio

Is TRI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRI income statement (TTM)
Revenue	AU$888.83k
Cost of Revenue	AU$0
Gross Profit	AU$888.83k
Other Expenses	AU$2.32m
Earnings	-AU$1.43m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0031
Gross Margin	100.00%
Net Profit Margin	-161.41%
Debt/Equity Ratio	0%

How did TRI perform over the long term?

See historical performance and comparison

TRI Stock Overview

Risk Analysis

TrivarX Limited Competitors

ASX:ICR

AU$5.4m

ASX:GLH

AU$8.0m

ASX:TD1

AU$4.9m

ASX:VFX

AU$11.7m

Price History & Performance

Recent News & Updates

TrivarX Limited, Annual General Meeting, Nov 28, 2024

TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024

New major risk - Financial position

Less than half of directors are independent

TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Less than half of directors are independent

Recent updates

TrivarX Limited, Annual General Meeting, Nov 28, 2024

TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024

New major risk - Financial position

Less than half of directors are independent

TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Less than half of directors are independent

Medibio Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Medibio Limited, Annual General Meeting, Oct 06, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Less than half of directors are independent

First half 2023 earnings released

Medibio Limited Appoints Christopher Ntoumenopoulos as Director

Less than half of directors are independent

Medibio Limited Announces Resignation of Stephen Mitchley as a Director

Medibio Limited Appoints David Trimboli as the Company's New Non-Executive Chair

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Limited, Annual General Meeting, Nov 11, 2022

Medibio Limited Appoints Thomas R. Young as CEO

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Appoints David Trimboli to Its Board of Directors as Non-Executive Director

Medibio Limited Announces Sleep Analysis Depressive Burden Study Clinical Trial Commencement

Medibio Limited Announces Resignation of Claude Solitario as Managing Director

Medibio Limited Announces Executive Changes

Medibio Limited Announces That A DSM-V1 Diagnosis Will Be Included as Primary Comparator for the Purposes of Assessing the Efficacy of Its Depression Algorithms, MEB-001

Less than half of directors are independent

Medibio Limited Appoints Matt Mesnik as Non-Executive Director

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Medibio Limited Appoints Stephen Mitchley as Non-Executive Director

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2020)

Medibio Limited to Resubmit FDA 510(K) Application for its Sleep Staging Software, MEBbsleep

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Medibio Limited, Annual General Meeting, Mar 24, 2021

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Medibio Limited Receives CE Mark Approval for Its Sleep Staging Software, MEBsleep

Medibio Limited Commences the Initial Phase of Testing of its Consumer Mental Health App

Medibio Limited Announces US FDA Advises Further Data Needed for Mebsleep Approval

Medibio Limited Signs Global Master License & Services Agreement with Compass Group Plc

Medibio Limited Signs Clinical Trial Agreement with MedBridge Healthcare

Medibio Limited Submits Request for FDA Breakthrough Device Designation

Full year earnings released - AU$0.0044 loss per share

Full year earnings released - AU$0.0044 loss per share

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.517195 million.

Shareholder Returns

Price Volatility

About the Company

TrivarX Limited Fundamentals Summary

8.2x

-5.1x

Earnings & Revenue